Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Herpes simplex virus vaccine

Inactive Publication Date: 2019-04-04
GEN VEC INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a nucleic acid sequence that is related to herpes simplex virus (HSV), and also a vector that can deliver this sequence to a mammal. When the mammal receives this sequence, it can produce a polypeptide that helps to fight the virus. The invention also covers methods for using these compositions to prevent or treat HSV disease. The invention also includes the use of multiple administrations to boost the immune response against HSV. Overall, the invention provides a way to protect against and treat herpes simplex virus infections in mammals.

Problems solved by technology

In addition, large scale international studies have shown the ineffectiveness of antiviral therapy of HSV-2 to reduce HIV-1 acquisition and demonstrated the inability of acyclovir to reduce transmission between HIV-1 discordant couples.
These disappointing findings indicate that the stimulation of neutralizing antibodies is insufficient for an effective HSV-2 vaccine.
More specifically, these results suggest that immunization with envelope proteins for induction of neutralizing antibodies is inadequate to generate an effective HSV vaccine.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Herpes simplex virus vaccine
  • Herpes simplex virus vaccine
  • Herpes simplex virus vaccine

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0103]This example demonstrates the construction of an adenovirus comprising the inventive nucleic acid sequence encoding an HSV antigen.

[0104]A human serotype 28 adenoviral vector was prepared with a deletion in the E1 region, the replacement of the hexon region with the hexon region of a human serotype 45 adenovirus, and the insertion of the nucleic acid sequence comprising SEQ ID NO: 5 (Ad28UL19 H(Ad45)). Ad28UL19 H(Ad45) is replication-deficient due to the deletion of the essential function provided by E1. The CMV promoter and transgene expression cassette comprising SEQ ID NO: 5 were introduced in place of the E1 sequences. The expression cassette, located at the E1 region deletion junction, is right-to-left with respect to the viral genome.

[0105]Ad28UL19 H(Ad45) has an E1 region deletion of bases 462 through 3111 of the Ad28 genomic sequence. The deletion includes Ad28 E1A and part of the E1B early proteins, which renders the vector replication incompetent in noncomplementing ...

example 2

[0108]This example describes animal models for the evaluation of antiviral efficacy.

[0109]Mouse Model of Primary HSV-1 / HSV-2 Challenge:

[0110]The primary screening model provides a rapid initial evaluation of antiviral efficacy against HSV primary infection with both clinical and virological endpoints. This model utilizes intravaginal inoculation of female mice (25 g) with HSV-1 or HSV-2 to evaluate potential antiviral therapies as well as vaccine / adjuvant candidates. Animals are followed daily for signs and systems of herpes disease, and vaginal swabs are obtained to evaluate the effect of therapy on viral replication. Single or combined antiviral therapies can be administered by any suitable means, including, but not limited to, topically, orally or systemically, and can be given at varying intervals begun before or after viral challenge. Dose range studies also can be carried out.

[0111]Dose and route of administration are individualized for each experimental agent. However, for ea...

example 3

[0124]This example demonstrates that the administration of a vector comprising one or more nucleic acid sequences encoding one or more HSV antigens induces an immune response (T cell response) against HSV.

[0125]Two modified serotype 28 adenoviral vectors comprising hexon and fiber from a serotype 45 adenoviral vector (Ad28 H / F) were produced using the methods described in Example 1. The first vector comprised a nucleic acid sequence comprising SEQ ID NO: 7 (a wild-type (non-modified) UL47; designated LW01), while the second vector comprised a nucleic acid sequence comprising SEQ ID NO: 5 (inventive UL19 nucleic acid sequence; designated LW02).

[0126]T cell response in mice following a single intramuscular administration of each adenoviral vector-delivered antigen (1×109 PU) was compared to natural infection (1×106 PFU of HSV administered intravaginally) as described in Example 2. Animals infected with HSV showed symptoms of HSV infection. As a negative control, animals were injected ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Weightaaaaaaaaaa
Login to View More

Abstract

Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This patent application is a continuation of copending U.S. patent application Ser. No. 15 / 618,740, filed Jun. 9, 2017, which is a continuation of U.S. patent application Ser. No. 14 / 403,397, filed Nov. 24, 2014, now U.S. Pat. No. 9,676,824, which is the U.S. national stage of International Patent Application No. PCT / US2013 / 041358, filed May 16, 2013, which claims the benefit of U.S. Provisional Patent Application 61 / 760,426, filed Feb. 4, 2013, and U.S. Provisional Patent Application 61 / 652,404, filed May 29, 2012, which applications are incorporated by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]This invention was made with Government support under Grant Number 5R43A1077147-02 awarded by the National Institutes of Health. The Government has certain rights in this invention.INCORPORATION-BY-REFERENCE OF MATERIAL ELECTRONICALLY SUBMITTED[0003]Incorporated by reference in its entirety herein is a compute...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/005A61K39/12A61K39/245C12N7/00A61K39/00
CPCC12N7/00A61K39/12C12N2710/10043A61K2039/545C07K14/005A61K39/245C12N2799/022C12N2710/16634C12N2710/16622A61K2039/53C12N2800/22
Inventor WEI, LISABROUGH, DOUGLAS E.LAZARSKI, CHRISTOPHER
Owner GEN VEC INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com